

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Anti-SLC3A1 polyclonal antibody

RRID:AB_2675975

Type: Antibody

Proper Citation

Atlas Antibodies Cat# HPA038360, RRID:AB_2675975

Antibody Information

URL: http://antibodyregistry.org/AB_2675975

Proper Citation: Atlas Antibodies Cat# HPA038360, RRID:AB_2675975

Target Antigen: SLC3A1

Host Organism: rabbit

Clonality: polyclonal

Comments: Originating manufacturer of this product. Applications: IHC, WB. Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues. Immunogen: Recombinant Protein Epitope Signature Tag (PrEST).

Antibody Name: Anti-SLC3A1 polyclonal antibody

Description: This polyclonal targets SLC3A1

Target Organism: human

Antibody ID: AB_2675975

Vendor: Atlas Antibodies

Catalog Number: HPA038360

Record Creation Time: 20231110T034205+0000

Record Last Update: 20260831T212605+0000

Ratings and Alerts

- Antibody validation available from The Human Protein Atlas - Human Protein Atlas <https://www.proteinatlas.org/search/HPA038360>

No alerts have been found for Anti-SLC3A1 polyclonal antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Vishy CE, et al. (2024) Genetics of cystogenesis in base-edited human organoids reveal therapeutic strategies for polycystic kidney disease. Cell stem cell, 31(4), 537.

Tran T, et al. (2022) A scalable organoid model of human autosomal dominant polycystic kidney disease for disease mechanism and drug discovery. Cell stem cell, 29(7), 1083.

Monteil V, et al. (2020) Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, 181(4), 905.